Beijing, Mar 16 (efe-epa).- China has given an emergency use approval for a new Covid-19 vaccine, local media reported on Tuesday.
The recombinant protein subunit vaccine is the first of its kind to be authorized for clinical use in the Asian country.
The vaccine, developed jointly by Anhui Zhifei Longcom Biopharmaceutical and the Chinese Academy of Sciences (CAS), has been approved by regulators to be given to people in certain cases, according to CAS’ Institute of Microbiology.
In November, the vaccine entered its third phase of human trials in China, Ecuador, Pakistan, Indonesia, Uzbekistan, a country that has also given the green light for its use.
This is the fifth such vaccine to be authorized for emergency use in China, which has also approved four vaccines from the companies Sinopharm, CanSino and Sinovac.
A total of 16 coronavirus vaccine candidates developed in China are now in clinical trials, a Chinese official said back in January.
China has vaccinated about 65 million people, a senior official at the National Health Commission said on Monday.
The Asian country plans to inoculate between 70% and 80% of its population by the end of this year or mid-2022.EFE-EPA